Hematologic toxicity of concurrent administration of Radium-223 and next generation anti-androgen therapies

PURPOSE/OBJECTIVES: Radium-223 is a first-in-class radiopharmaceutical recently approved for the treatment of castration-resistant prostate cancer (CRPC) in patients with symptomatic bone metastases. Initial studies investigating Radium-223 primarily utilized non-steroidal first-generation anti-andr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Clin Oncol
Autors principals: Dan, Tu D., Eldredge-Hindy, Harriet B., Hoffman-Censits, Jean, Lin, Jianqing, Kelly, William K., Gomella, Leonard G., Lallas, Costas D., Trabulsi, Edouard J., Hurwitz, Mark D., Dicker, Adam P., Den, Robert B.
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4549230/
https://ncbi.nlm.nih.gov/pubmed/25723740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0000000000000181
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars